MKI67 and breast carcinoma: The nuclear proliferation marker Ki-67 has potential utility in the clinical management of breast cancer.7–9 Several studies have demonstrated that Ki-67 values after preoperative chemotherapy are indicative of prognosis.10,11 Therefore, it may be hypothesised that Ki-67 is suitable as a biological response marker.